BioTime, Inc., a biotechnology company, focuses on developing cell based therapeutic products for neurological disorders, cancer, age related macular degeneration, orthopedic disorders, and age-related cardiovascular diseases. Products The company is also pursuing commercial opportunities such as: Renevia a product in clinical trials in Europe to facilitate cell transplantation; ReGlyde and Premvia for tendon and wound-management applications, respectively; PanC-Dx, a family of novel blood and urine-based cancer screens; a line of research products, including PureStem human embryonic progenitor cell lines (hEPSc), associated ESpan culture media, human embryonic stem cell lines derived by its subsidiary ES Cell International Pte Ltd (ESI) under good manufacturing practices (cGMP); HyStem hydrogel products; and the LifeMap Database Suite, and mobile health software products. The company also has developed and out-licensed manufacturing and marketing rights to Hextend, a physiologically balanced blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. Hextend maintains circulatory system fluid volume and blood pressure and helps sustain vital organs during surgery or when a patient has sustained substantial blood loss due to an injury. Hextend is the only blood plasma volume expander that contains lactate, multiple electrolytes, glucose, and a medically approved form of starch called hetastarch. Research and Development During 2014, the company spent $37,532,624 on research and development. Customers The company’s customers include Hospira, Inc.; CJ HealthCare Corporation; and Stemcell Technologies. Intellectual Property As of March 8, 2015, the company owned or controlled or licensed directly or through its subsidiaries approximately 800 patents and pending patent applications worldwide. The company also licensed approximately 140 patents and applications from Wisconsin Alumni Research Foundation. Espy, HyStem, Hextend, PureStem, and PentaLyte are registered trademarks of BioTime, Inc.; and Renevia, ReGlyde, Premvia, ESpan and ESI BIO are trademarks of BioTime, Inc. ACTCellerate is a trademark licensed to the company by Advanced Cell Technology, Inc., now Ocata Therapeutics, Inc., (Ocata). ReCyte is a trademark of ReCyte Therapeutics, Inc. PanC-Dx is a trademark of OncoCyte Corporation. OpRegen is a registered trademark of Cell Cure Neurosciences, Ltd. GeneCards is a registered trademark of Yeda Research and Development Co. Ltd. Strategy The company’s business strategy includes the development and sale of advanced human stem cell products and technologies that could be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. History BioTime, Inc. was founded in 1990. The company was incorporated in 1990 in the state of California.
biotime inc (BTX:NYSE Amex)
1301 Harbor Bay Parkway
Alameda, CA 94502
|Fibrocell Science Inc||$5.79 USD||-0.20|
|Mesoblast Ltd||A$1.76 AUD||-0.035|
|Ocata Therapeutics Inc||$8.58 USD||+0.02|
|Organovo Holdings Inc||$3.36 USD||-0.03|
|ReproCELL Inc||¥434.00 JPY||-12.00|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact BIOTIME INC, please visit www.biotimeinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.